Company: GRCE
Filing Date: 2025-07-28
Form Type: DEF 14A
Source: 0001140361-25-027456
Chunk: 41

Company: Grace Therapeutics, Inc.
Filing Date: 2025-07-28
Form: DEF 14A
Chunk 41
---
                | 86,806 |     |                  | $2.64 |     |          | July 14, 2033     |     |                   |
|                         | December 19, 2023 |     |                   |  41,668 |     |                |      — |     |                  | $2.13 |     |          | December 19, 2033 |     |                   |
|                         | May 6, 2024       |     |                   |  32,193 |     |                | 96,577 |     |                  | $2.96 |     |          | May 6, 2034       |     |                   |
| Amresh Kumar            |                   |     | July 14, 2023     |         |     |         24,500 |        |     |           17,500 |       |     |    $2.64 |                   |     | July 14, 2033     |
|                         | May 6, 2024       |     |                   |   4,935 |     |                | 14,805 |     |                  | $2.96 |     |          | May 6, 2034       |     |                   |
| Carrie D’Andrea         |                   |     | July 14, 2023     |         |     |         24,500 |        |     |           17,500 |       |     |    $2.64 |                   |     | July 14, 2033     |
|                         | May 6, 2024       |     |                   |   4,935 |     |                | 14,805 |     |                  | $2.96 |     |          | May 6, 2034       |     |                   |

| (1) | The option awards and exercise prices listed above have been adjusted to account for the Company’s 1-for-6 reverse stock split, which was effective on July 10, 2023. The option awards listed in the table above vest with respect to 1/12 on each quarterly anniversary thereafter over the following three years, subject to the executive officer’s continuous service with the Company through the vesting date. The option awards listed above will be cancelled 90 days after the termination date, as per the Acasti Pharma Inc. Stock Option Plan. |

25

TABLE OF CONTENTS

Required Tabular Disclosure of